Bacillus Calmette–Guérin Treatment Changes the Tumor Microenvironment of Non-Muscle-Invasive Bladder Cancer
BackgroundBacillus Calmette–Guérin (BCG) is currently the most effective intravesical therapy for non-muscle-invasive bladder cancer (NMIBC) as it can prevent disease recurrence and progression and lower mortality. However, the response rates to BCG vary widely and are dependent on a multitude of fa...
Main Authors: | Fei Su, Ming Liu, Wei Zhang, Min Tang, Jinsong Zhang, Hexin Li, Lihui Zou, Rui Zhang, Yudong Liu, Lin Li, Jie Ma, Yaqun Zhang, Meng Chen, Fei Xiao |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-03-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.842182/full |
Similar Items
-
Breast abscess due to Bacillus Calmette-Guérin
by: Aurélien Dinh, et al.
Published: (2017-06-01) -
Bacillus Calmette–Guérin and Bladder Cancer
by: Azad H.A. Razack
Published: (2007-10-01) -
The impact of Bacillus Calmette-Guérin (BCG) vaccination on the course of COVID-19
by: Jakub Krzysztof Gałązka
Published: (2022-10-01) -
Adverse reactions due to the bacillus Calmette-Guerin vaccine: Twenty Tunisian cases
by: Khadija Sellami, et al.
Published: (2018-01-01) -
Measles infection causing Bacillus Calmette-Guérin reactivation: a case report
by: Sobana Muthuvelu, et al.
Published: (2019-07-01)